TUESDAY, June 6, 2023 (HealthDay News) -- For outpatient treatment of COVID-19, nirmatrelvir-ritonavir is effective for reducing 30-day hospitalization or death, while molnupiravir is associated with a reduction in 30-day mortality, according to a study published online June 6 in…
